# JADE (NCT06256588)

> A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06256588
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms, Head and Neck
- Interventions: Dostarlimab; Placebo
- Enrollment: 864
- Primary outcome: Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=jade-nct06256588